For instance, in a phase 3 clinical trial on FLT3 mutation positive R/R AML patients, gilteritinib single agent significantly prolonged survival: the median overall survival (OS) was 9.3 months in the gilteritinib treatment group, while 5.6 months in the standard chemotherapy treatment group [21]. The gene discussed is FLT3; the disease is acute myeloid leukemia.